APO Research
Talk to an analyst

APO RESEARCH · REPORT

Helicobacter Pylori Infection Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Helicobacter Pylori Infection Treatment Market Outlook and Growth Opportunities 2026

4 July 2026195 pages

Choose your research edition.

Industry ResearchHelicobacter Pylori Infection Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Helicobacter Pylori Infection Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Helicobacter Pylori Infection Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Helicobacter Pylori Infection Treatment Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Helicobacter Pylori Infection Treatment Market Analysis and Forecast 2026-2032172 pages · $4,950 USD

Market perspective

The global Helicobacter Pylori Infection Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Helicobacter Pylori Infection Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Helicobacter Pylori Infection Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Helicobacter Pylori Infection Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Helicobacter Pylori Infection Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Helicobacter Pylori Infection Treatment market include Cumberland Pharmaceuticals, Eisai Co., Bio-Rad Laboratories, F. Hoffmann-La Roche, Alpha Laboratories, Biohit, Phathom Pharmaceuticals, Redhill Biopharma and Takeda Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Helicobacter Pylori Infection Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Helicobacter Pylori Infection Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Helicobacter Pylori Infection Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Helicobacter Pylori Infection Treatment market.

Helicobacter Pylori Infection Treatment Segment by Company

Cumberland Pharmaceuticals

Eisai Co.

Bio-Rad Laboratories

F. Hoffmann-La Roche

Alpha Laboratories

Biohit

Phathom Pharmaceuticals

Redhill Biopharma

Takeda Pharmaceuticals

AbbVie

Helicobacter Pylori Infection Treatment Segment by Type

Bismuth-quadruple Therapy

Concomitant Therapy

Levofloxacin Triple Therapy

Bismuth Therapy

High-dose Dual Therapy

Helicobacter Pylori Infection Treatment Segment by Application

Hospitals

Diagnostics Laboratories

Clinics

Helicobacter Pylori Infection Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Helicobacter Pylori Infection Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Helicobacter Pylori Infection Treatment key companies, revenue, market share, and recent developments.

3. To split the Helicobacter Pylori Infection Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Helicobacter Pylori Infection Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Helicobacter Pylori Infection Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Helicobacter Pylori Infection Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Helicobacter Pylori Infection Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Helicobacter Pylori Infection Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Helicobacter Pylori Infection Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Helicobacter Pylori Infection Treatment industry.

Chapter 3: Detailed analysis of Helicobacter Pylori Infection Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Helicobacter Pylori Infection Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Helicobacter Pylori Infection Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Helicobacter Pylori Infection Treatment Industry Trends Table 2. Helicobacter Pylori Infection Treatment Industry Drivers Table 3. Helicobacter Pylori Infection Treatment Industry Opportunities and Challenges Table 4. Helicobacter Pylori Infection Treatment Industry Restraints Table 5. Global Helicobacter Pylori Infection Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Helicobacter Pylori Infection Treatment Revenue Share by Company (2021-2026) Table 7. Global Helicobacter Pylori Infection Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Helicobacter Pylori Infection Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Helicobacter Pylori Infection Treatment Company, Product Type & Application Table 10. Global Helicobacter Pylori Infection Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Helicobacter Pylori Infection Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Bismuth-quadruple Therapy Table 15. Significant Companies of Concomitant Therapy Table 16. Significant Companies of Levofloxacin Triple Therapy Table 17. Significant Companies of Bismuth Therapy Table 18. Significant Companies of High-dose Dual Therapy Table 19. Global Helicobacter Pylori Infection Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Helicobacter Pylori Infection Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Helicobacter Pylori Infection Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Helicobacter Pylori Infection Treatment Sales Value Share by Type (2021-2026) Table 23. Global Helicobacter Pylori Infection Treatment Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Diagnostics Laboratories Table 26. Significant Companies of Clinics Table 27. Global Helicobacter Pylori Infection Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Helicobacter Pylori Infection Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Helicobacter Pylori Infection Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Helicobacter Pylori Infection Treatment Sales Value Share by Application (2021-2026) Table 31. Global Helicobacter Pylori Infection Treatment Sales Value Share by Application (2027-2032) Table 32. Global Helicobacter Pylori Infection Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Helicobacter Pylori Infection Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Helicobacter Pylori Infection Treatment Sales Value Share by Region (2021-2026) Table 35. Global Helicobacter Pylori Infection Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Helicobacter Pylori Infection Treatment Sales Value Share by Region (2027-2032) Table 37. Global Helicobacter Pylori Infection Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Helicobacter Pylori Infection Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Helicobacter Pylori Infection Treatment Sales Value Market Share by Country (2021-2026) Table 40. Global Helicobacter Pylori Infection Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Helicobacter Pylori Infection Treatment Sales Value Market Share by Country (2027-2032) Table 42. Cumberland Pharmaceuticals Company Information Table 43. Cumberland Pharmaceuticals Business Overview Table 44. Cumberland Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Cumberland Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio Table 46. Cumberland Pharmaceuticals Recent Development Table 47. Eisai Co. Company Information Table 48. Eisai Co. Business Overview Table 49. Eisai Co. Helicobacter Pylori Infection Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Eisai Co. Helicobacter Pylori Infection Treatment Product Portfolio Table 51. Eisai Co. Recent Development Table 52. Bio-Rad Laboratories Company Information Table 53. Bio-Rad Laboratories Business Overview Table 54. Bio-Rad Laboratories Helicobacter Pylori Infection Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Bio-Rad Laboratories Helicobacter Pylori Infection Treatment Product Portfolio Table 56. Bio-Rad Laboratories Recent Development Table 57. F. Hoffmann-La Roche Company Information Table 58. F. Hoffmann-La Roche Business Overview Table 59. F. Hoffmann-La Roche Helicobacter Pylori Infection Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. F. Hoffmann-La Roche Helicobacter Pylori Infection Treatment Product Portfolio Table 61. F. Hoffmann-La Roche Recent Development Table 62. Alpha Laboratories Company Information Table 63. Alpha Laboratories Business Overview Table 64. Alpha Laboratories Helicobacter Pylori Infection Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Alpha Laboratories Helicobacter Pylori Infection Treatment Product Portfolio Table 66. Alpha Laboratories Recent Development Table 67. Biohit Company Information Table 68. Biohit Business Overview Table 69. Biohit Helicobacter Pylori Infection Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Biohit Helicobacter Pylori Infection Treatment Product Portfolio Table 71. Biohit Recent Development Table 72. Phathom Pharmaceuticals Company Information Table 73. Phathom Pharmaceuticals Business Overview Table 74. Phathom Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Phathom Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio Table 76. Phathom Pharmaceuticals Recent Development Table 77. Redhill Biopharma Company Information Table 78. Redhill Biopharma Business Overview Table 79. Redhill Biopharma Helicobacter Pylori Infection Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Redhill Biopharma Helicobacter Pylori Infection Treatment Product Portfolio Table 81. Redhill Biopharma Recent Development Table 82. Takeda Pharmaceuticals Company Information Table 83. Takeda Pharmaceuticals Business Overview Table 84. Takeda Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Takeda Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio Table 86. Takeda Pharmaceuticals Recent Development Table 87. AbbVie Company Information Table 88. AbbVie Business Overview Table 89. AbbVie Helicobacter Pylori Infection Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AbbVie Helicobacter Pylori Infection Treatment Product Portfolio Table 91. AbbVie Recent Development Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Helicobacter Pylori Infection Treatment Product Image Figure 2. Global Helicobacter Pylori Infection Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Helicobacter Pylori Infection Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Helicobacter Pylori Infection Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Bismuth-quadruple Therapy Image Figure 8. Concomitant Therapy Image Figure 9. Levofloxacin Triple Therapy Image Figure 10. Bismuth Therapy Image Figure 11. High-dose Dual Therapy Image Figure 12. Global Helicobacter Pylori Infection Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Helicobacter Pylori Infection Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Helicobacter Pylori Infection Treatment Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Diagnostics Laboratories Image Figure 17. Clinics Image Figure 18. Global Helicobacter Pylori Infection Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Helicobacter Pylori Infection Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Helicobacter Pylori Infection Treatment Sales Value Share by Application (2021-2032) Figure 21. Global Helicobacter Pylori Infection Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Helicobacter Pylori Infection Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Helicobacter Pylori Infection Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. North America Helicobacter Pylori Infection Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Helicobacter Pylori Infection Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Helicobacter Pylori Infection Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Helicobacter Pylori Infection Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Helicobacter Pylori Infection Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Helicobacter Pylori Infection Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. South America Helicobacter Pylori Infection Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Helicobacter Pylori Infection Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Helicobacter Pylori Infection Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Bismuth-quadruple Therapy
  • Concomitant Therapy
  • Levofloxacin Triple Therapy
  • Bismuth Therapy
  • High-dose Dual Therapy
Applications
  • Hospitals
  • Diagnostics Laboratories
  • Clinics
Companies covered
  • Cumberland Pharmaceuticals
  • Eisai Co.
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche
  • Alpha Laboratories
  • Biohit
  • Phathom Pharmaceuticals
  • Redhill Biopharma
  • Takeda Pharmaceuticals
  • AbbVie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Helicobacter Pylori Infection Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Helicobacter Pylori Infection Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Helicobacter Pylori Infection Treatment Market Dynamics
  1. 2.1 Helicobacter Pylori Infection Treatment Industry Trends
  2. 2.2 Helicobacter Pylori Infection Treatment Industry Drivers
  3. 2.3 Helicobacter Pylori Infection Treatment Industry Opportunities and Challenges
  4. 2.4 Helicobacter Pylori Infection Treatment Industry Restraints
3 Helicobacter Pylori Infection Treatment Market by Company
  1. 3.1 Global Helicobacter Pylori Infection Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Helicobacter Pylori Infection Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Helicobacter Pylori Infection Treatment Company Ranking (2024-2026)
  4. 3.4 Global Helicobacter Pylori Infection Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Helicobacter Pylori Infection Treatment Company Product Type and Application
  6. 3.6 Global Helicobacter Pylori Infection Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Helicobacter Pylori Infection Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Helicobacter Pylori Infection Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Helicobacter Pylori Infection Treatment Market by Type
  1. 4.1 Helicobacter Pylori Infection Treatment Type Introduction
  2. 4.1.1 Bismuth-quadruple Therapy
  3. 4.1.2 Concomitant Therapy
  4. 4.1.3 Levofloxacin Triple Therapy
  5. 4.1.4 Bismuth Therapy
  6. 4.1.5 High-dose Dual Therapy
  7. 4.2 Global Helicobacter Pylori Infection Treatment Sales Value by Type
  8. 4.2.1 Global Helicobacter Pylori Infection Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Helicobacter Pylori Infection Treatment Sales Value by Type (2021-2032)
  10. 4.2.3 Global Helicobacter Pylori Infection Treatment Sales Value Share by Type (2021-2032)
5 Helicobacter Pylori Infection Treatment Market by Application
  1. 5.1 Helicobacter Pylori Infection Treatment Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Diagnostics Laboratories
  4. 5.1.3 Clinics
  5. 5.2 Global Helicobacter Pylori Infection Treatment Sales Value by Application
  6. 5.2.1 Global Helicobacter Pylori Infection Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Helicobacter Pylori Infection Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Helicobacter Pylori Infection Treatment Sales Value Share by Application (2021-2032)
6 Helicobacter Pylori Infection Treatment Regional Value Analysis
  1. 6.1 Global Helicobacter Pylori Infection Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Helicobacter Pylori Infection Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Helicobacter Pylori Infection Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Helicobacter Pylori Infection Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Helicobacter Pylori Infection Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Helicobacter Pylori Infection Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Helicobacter Pylori Infection Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Helicobacter Pylori Infection Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Helicobacter Pylori Infection Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Helicobacter Pylori Infection Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Helicobacter Pylori Infection Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Helicobacter Pylori Infection Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Helicobacter Pylori Infection Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Helicobacter Pylori Infection Treatment Sales Value Share by Country, 2025 VS 2032
7 Helicobacter Pylori Infection Treatment Country-level Value Analysis
  1. 7.1 Global Helicobacter Pylori Infection Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Helicobacter Pylori Infection Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Helicobacter Pylori Infection Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Helicobacter Pylori Infection Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Helicobacter Pylori Infection Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Helicobacter Pylori Infection Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Helicobacter Pylori Infection Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Cumberland Pharmaceuticals
  2. 8.1.1 Cumberland Pharmaceuticals Company Information
  3. 8.1.2 Cumberland Pharmaceuticals Business Overview
  4. 8.1.3 Cumberland Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Cumberland Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio
  6. 8.1.5 Cumberland Pharmaceuticals Recent Developments
  7. 8.2 Eisai Co.
  8. 8.2.1 Eisai Co. Company Information
  9. 8.2.2 Eisai Co. Business Overview
  10. 8.2.3 Eisai Co. Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Co. Helicobacter Pylori Infection Treatment Product Portfolio
  12. 8.2.5 Eisai Co. Recent Developments
  13. 8.3 Bio-Rad Laboratories
  14. 8.3.1 Bio-Rad Laboratories Company Information
  15. 8.3.2 Bio-Rad Laboratories Business Overview
  16. 8.3.3 Bio-Rad Laboratories Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bio-Rad Laboratories Helicobacter Pylori Infection Treatment Product Portfolio
  18. 8.3.5 Bio-Rad Laboratories Recent Developments
  19. 8.4 F. Hoffmann-La Roche
  20. 8.4.1 F. Hoffmann-La Roche Company Information
  21. 8.4.2 F. Hoffmann-La Roche Business Overview
  22. 8.4.3 F. Hoffmann-La Roche Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 F. Hoffmann-La Roche Helicobacter Pylori Infection Treatment Product Portfolio
  24. 8.4.5 F. Hoffmann-La Roche Recent Developments
  25. 8.5 Alpha Laboratories
  26. 8.5.1 Alpha Laboratories Company Information
  27. 8.5.2 Alpha Laboratories Business Overview
  28. 8.5.3 Alpha Laboratories Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Alpha Laboratories Helicobacter Pylori Infection Treatment Product Portfolio
  30. 8.5.5 Alpha Laboratories Recent Developments
  31. 8.6 Biohit
  32. 8.6.1 Biohit Company Information
  33. 8.6.2 Biohit Business Overview
  34. 8.6.3 Biohit Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Biohit Helicobacter Pylori Infection Treatment Product Portfolio
  36. 8.6.5 Biohit Recent Developments
  37. 8.7 Phathom Pharmaceuticals
  38. 8.7.1 Phathom Pharmaceuticals Company Information
  39. 8.7.2 Phathom Pharmaceuticals Business Overview
  40. 8.7.3 Phathom Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Phathom Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio
  42. 8.7.5 Phathom Pharmaceuticals Recent Developments
  43. 8.8 Redhill Biopharma
  44. 8.8.1 Redhill Biopharma Company Information
  45. 8.8.2 Redhill Biopharma Business Overview
  46. 8.8.3 Redhill Biopharma Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Redhill Biopharma Helicobacter Pylori Infection Treatment Product Portfolio
  48. 8.8.5 Redhill Biopharma Recent Developments
  49. 8.9 Takeda Pharmaceuticals
  50. 8.9.1 Takeda Pharmaceuticals Company Information
  51. 8.9.2 Takeda Pharmaceuticals Business Overview
  52. 8.9.3 Takeda Pharmaceuticals Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Takeda Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio
  54. 8.9.5 Takeda Pharmaceuticals Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie Helicobacter Pylori Infection Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Helicobacter Pylori Infection Treatment Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst